Histone deacetylase inhibitors: recent outcomes from clinical trials and the implications for oncology treatment approaches

By Marsh Alexandra MR   Narramore Ruth   Chapple Keith   Lobo Alan J   Wild Jonathan RL   Corfe Bernard M  

Clinical Investigation, Vol. 3, Iss. 6, 2013-06 ,pp. : 571-594

Future Science

Access to resources Recommend Favorite

Histone deacetylase inhibitors in cancer: What have we learned?

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : 1164-1167

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down‐regulating EGFR expression

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 15, 2015-08 ,pp. : 3817-3830

John Wiley & Sons Inc

Access to resources Recommend Favorite

The effects of DNA methyltransferase inhibitors and histone deacetylase inhibitors on digit regeneration in mice

By Wang Gang   Badylak Stephen F   Heber-Katz Ellen   Braunhut Susan J   Gudas Lorraine J  

Regenerative Medicine, Vol. 5, Iss. 2, 2010-03 ,pp. : 201-220

Future Medicine

Access to resources Recommend Favorite

Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line

By              

International Journal of Molecular Medicine, Vol. 28, Iss. 6, 2011-01 ,pp. : 985-991

Spandidos Publications

Access to resources Recommend Favorite